No Data
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Sinco Pharma (06833.HK) plans to hold a board of directors meeting on August 28th to approve the interim performance.
Sinco Pharma (06833.HK) announced on August 16th that the board of directors meeting will be held on Wednesday, August 28th, 2024 to approve the unaudited interim performance of the company and its subsidiaries for the six months ended June 30th, 2024 (including), and consider recommending the distribution of interim dividends (if any), as well as dealing with other matters.
SINCO PHARMA: DATE OF BOARD MEETING
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
No Data
